News | June 12, 2022
Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Subscribe To Our Newsletter & Stay Updated
